Physician profile
Manish Gopal
NPI 1205981230
$6,542.73
in general payments reported to CMS, 2019-2025
26 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $2,091 · 2021: $555 · 2022: $654 · 2023: $1,072 · 2024: $1,097 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101 · Travel and Lodging: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.14 |
| Travel and Lodging | $600.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $3,550.83 | 2020-2025 | Desara |
| Coloplast Corp | $588.62 | 2019-2025 | Saffron |
| Bluewind Medical | $582.48 | 2024-2025 | Revi |
| Astellas Pharma US INC | $468.57 | 2019-2024 | Veozah, Myrbetriq |
| Biotissue Holdings INC. | $315.27 | 2025 | |
| Pfizer INC. | $287.51 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $202.24 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $194.22 | 2019-2024 | Solyx Sis System |
| Abbvie INC. | $71.10 | 2019-2020 | |
| Urovant Sciences INC | $46.54 | 2021-2022 | |
| Axonics, INC. | $31.10 | 2020-2022 | |
| Hologic Sales and Service, LLC | $18.99 | 2022 | |
| Olympus America INC. | $18.38 | 2025 | Hd Camera Head |
| Allergan, INC. | $16.88 | 2022 | |
| Medtronic, INC. | $16.82 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Ih INC. | $16.50 | 2021 | |
| Millicent US INC | $16.27 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.16 | 2020 | |
| Therapeuticsmd, INC. | $14.75 | 2019 | |
| Daiichi Sankyo INC. | $14.73 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.57 | 2023 | Seglentis |
| Novo Nordisk INC | $13.33 | 2022 | |
| Medtronic USA, INC. | $11.71 | 2019 | |
| Escala Medical INC. | $9.38 | 2025 | |
| Meditrina | $6.78 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Gopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.